Moberg Pharma: Positive surprises
Research Note
2019-10-01
08:04
Management once again demonstrates its commitment to building shareholder value by signing yet another significant licensing agreement for MOB-015. The deal with Taisho providing cash, making it possible to raise the shareholder payment to SEK 46.50 from the previously announced interval of SEK 43-45, but also to repay outstanding debt.
KP
Klas Palin
Disclosures and disclaimers